#BEGIN_DRUGCARD DB04043

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C35H49FeN5O12

# Chemical_IUPAC_Name:
(8Z)-9-[(1S,9S,12S,15R,22R,30S)-13,16,20,37-tetraoxo-2,10,17,28,29,36-hexaoxa-14,21,27,31,38-pentaaza-1-ferrahexacyclo[13.13.7.1^{1,31}.1^{9,12}.1^{22,27}.0^{3,8}]octatriaconta-3,5,7-trien-30-yl]non-8-enoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Carboxymycobactin T

# HET_ID:
CM2

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C35H50N5O12.Fe/c41-28-16-8-7-13-24(28)33-38-27(23-52-33)32(46)37-26(35(48)51-22-19-29(42)36-25-14-9-12-21-40(50)34(25)47)15-10-11-20-39(49)30(43)17-5-3-1-2-4-6-18-31(44)45;/h5,7-8,13,16-17,25-27,30,33,38,41H,1-4,6,9-12,14-15,18-23H2,(H,36,42)(H,37,46)(H,44,45);/q-3;+4/p-1/b17-5-;/t25-,26-,27+,30+,33+;/m1./s1

# InChI_Key:
InChIKey=GJJULHJRORAZCG-QMDLAEJKSA-M

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4043

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
787.635

# Molecular_Weight_Mono:
787.27271419

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1X8U

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
2.42

# Predicted_LogS:
-3.5

# Predicted_Water_Solubility:
2.40e-01 g/l

# Primary_Accession_No:
DB04043

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936871

# PubChem_Substance_ID:
46507675

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00952

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(=O)CCCCCC\C=C/[C@@H]1O[Fe@]23ON1CCCC[C@@H](NC(=O)[C@@H]1CO[C@H](N1)C1=CC=CC=C1O2)C(=O)OCCC(=O)N[C@@H]1CCCCN(O3)C1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:53 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
LCN2

# Drug_Target_1_GenBank_ID_Gene:
X83006

# Drug_Target_1_GenBank_ID_Protein:
929657

# Drug_Target_1_GeneCard_ID:
LCN2

# Drug_Target_1_Gene_Name:
LCN2

# Drug_Target_1_Gene_Sequence:
>597 bp
ATGCCCCTAGGTCTCCTGTGGCTGGGCCTAGCCCTGTTGGGGGCTCTGCATGCCCAGGCC
CAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGCAGCAG
AACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGAATGCA
ATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAAAGAA
GACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGGATC
AGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTTAC
CCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTATG
GTGTTCTTTAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA
ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGC
CTCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCTGA

# Drug_Target_1_General_Function:
Involved in lipophilic molecule transport

# Drug_Target_1_General_References:
10339412	Coles M, Diercks T, Muehlenweg B, Bartsch S, Zolzer V, Tschesche H, Kessler H: The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin. J Mol Biol. 1999 May 28;289(1):139-57.
10684642	Goetz DH, Willie ST, Armen RS, Bratt T, Borregaard N, Strong RK: Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry. 2000 Feb 29;39(8):1935-41.
1281792	Triebel S, Blaser J, Reinke H, Tschesche H: A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 1992 Dec 21;314(3):386-8.
7683678	Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993 May 15;268(14):10425-32.
7835423	Bartsch S, Tschesche H: Cloning and expression of human neutrophil lipocalin cDNA derived from bone marrow and ovarian cancer cells. FEBS Lett. 1995 Jan 9;357(3):255-9.
8060329	Bundgaard JR, Sengelov H, Borregaard N, Kjeldsen L: Molecular cloning and expression of a cDNA encoding NGAL: a lipocalin expressed in human neutrophils. Biochem Biophys Res Commun. 1994 Aug 15;202(3):1468-75.

# Drug_Target_1_HGNC_ID:
HGNC:6526

# Drug_Target_1_HPRD_ID:
02551

# Drug_Target_1_ID:
1782

# Drug_Target_1_Locus:
9q34

# Drug_Target_1_Molecular_Weight:
22588

# Drug_Target_1_Name:
Neutrophil gelatinase-associated lipocalin

# Drug_Target_1_Number_of_Residues:
198

# Drug_Target_1_PDB_ID:
1NGL

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00061	Lipocalin

# Drug_Target_1_Protein_Sequence:
>Neutrophil gelatinase-associated lipocalin precursor
MPLGLLWLGLALLGALHAQAQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNA
ILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIKSY
PGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLG
LPENHIVFPVPIDQCIDG

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-20

# Drug_Target_1_Specific_Function:
Transport of small lipophilic substances (Potential)

# Drug_Target_1_SwissProt_ID:
P80188

# Drug_Target_1_SwissProt_Name:
NGAL_HUMAN

# Drug_Target_1_Synonyms:
25 kDa alpha-2-microglobulin-related subunit of MMP-9
Lipocalin-2
NGAL
Neutrophil gelatinase-associated lipocalin precursor
Oncogene 24p3
p25

# Drug_Target_1_Theoretical_pI:
9.24

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB04043
